Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-sct
|
|
- Steven Harrell
- 5 years ago
- Views:
Transcription
1 Bone Marrow Transplantation (2013) 48, & 2013 Macmillan Publishers Limited All rights reserved /13 ORIGINAL ARTICLE Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-sct SV Glavey 1, MA Gertz 2, A Dispenzieri 2, S Kumar 2, F Buadi 2, M Lacy 2, SR Hayman 2, D Dingli 2, A McCurdy 2, WJ Hogan 2, DA Gastineau 2 and N Leung 2,3 Renal failure commonly complicates multiple myeloma (MM) and is associated with reduced survival. It is not clear whether auto- SCT results in improved renal function or attainment of independence from dialysis in patients with advanced renal impairment due to MM. We conducted a retrospective cohort study of all patients who underwent auto-sct for MM complicated by advanced renal failure at our institution over a 10-year period ( ). We aimed to assess the association between auto-sct and renal outcome in patients with serum creatinine (SCr) over 3 mg/dl, attributable to MM, including those who were dialysis dependent. Thirty patients (2.8% of all auto-sct patients) met inclusion criteria. Fourteen of 15 patients who were dialysis dependent before auto-sct remained dialysis dependent in the long term despite hematological response (HR). Of the remaining 15 patients with SCr 43 mg/dl, an improvement in glomerular filtration rate (GFR) from 15 to 19.4 ml/min/1.73 m 2 was noted post auto-sct (P ¼ 0.035); however, neither HR post auto-sct or pre-existing renal function were independently associated with renal outcome. Auto-SCT was not associated with independence from dialysis in patients with renal failure due to MM at our institution. Although auto-sct was associated with an improvement in GFR in patients with SCr 43 mg/dl, this improvement was not related to HR. Bone Marrow Transplantation (2013) 48, ; doi: /bmt ; published online 5 August 2013 Keywords: auto-sct; renal; dialysis INTRODUCTION Renal impairment is a common complication of multiple myeloma (MM) at presentation and is associated with a higher early mortality and reduced OS. 1,2 Blade et al. 3 reported that early recovery of renal function in MM is associated with improved survival. MM cast nephropathy is the pathology most often associated with severe renal impairment in these patients. The prevalence of renal failure at presentation of MM seen throughout the literature is of the order of 20 30%. 3,4 Approximately 8% of all patients with MM will require long-term dialysis, 3,5 8 and dialysisdependent renal failure is itself an independent poor prognostic factor for survival. 7 Auto-SCT following high-dose chemotherapy has been established as optimal therapy for patients with MM. 9,10 The introduction of novel agents to the transplant sequence has resulted in an unprecedented increase in PFS in recent years. Coupled to this success is the increased focus on individually tailored therapies for MM patients. For patients with advanced renal disease, freedom from dialysis is an important goal of therapy. Patients with milder degrees of renal impairment may avoid dialysis altogether, and the associated increased mortality, if an improvement in renal function can be attained with auto-sct. The current literature pertaining to renal recovery following auto- SCT is conflicting. Some studies have shown an improvement in renal function of up to 32 34%. 11,12 However, in patients receiving renal replacement therapy at the time of transplant, only 5 14% regain independence from dialysis following initial auto-sct for MM. 13,14 Despite a high rate of partial (PR) and complete () hematological response (HR) of MM in these studies conducted in the novel agent era, renal recovery was poor. The question of renal response following auto-sct is important for patients and clinicians, as they consider goals of therapy, particularly for dialysis-dependent patients. To address this question, we reviewed our experience in a retrospective cohort study using electronic medical records and renal biopsy data from all patients undergoing auto-sct for MM from 2000 to 2010 at Mayo Clinic, Rochester, MN, USA. MATERIALS AND METHODS We reviewed the records of all patients who underwent auto-sct for MM at Mayo Clinic, Rochester from 01/2000 to 01/2010. We selected, from the entire cohort, all patients who had advanced renal impairment defined as a serum creatinine (SCr) 43 mg/dl, or who were dialysis dependent at the time of transplantation. Although other studies have selected a cutoff of 2 mg/dl, we chose this higher level of SCr to select patients who were close to needing dialysis at the time of auto-sct, for whom attainment of a renal response was critical. All patients with end-stage kidney disease or chronic kidney disease not related to the development of MM were excluded. Patients who had developed acute renal failure in the days before auto-sct were also excluded. Clinical information for all patients was captured prospectively in a continuously updated database. Follow-up data were available until the time of death or the time of analysis on all patients. No patients were lost to follow-up. All patients provided written informed consent prospectively for use of their medical records and access to renal biopsy data. Approval was obtained for the study from the Mayo Clinic Institutional Review Board in accordance with federal regulations and the Declaration of Helsinki. Baseline demographics were recorded for all patients. The SCr level used in our analysis was the value measured immediately before auto-sct. We chose this value in order to isolate the effect of auto-sct on renal function from that of upfront therapy. In addition, creatinine clearance or iothalamate clearance (ml/min/1.73 m 2 ) 1 Department of Hematology, Galway University Hospital, Galway, Ireland; 2 Division of Nephrology, Mayo Clinic, Rochester, MN, USA and 3 Division of Hematology, Mayo Clinic, Rochester, MN, USA. Correspondence: Dr SV Glavey, Department of Hematology, Galway University Hospital, Newcastle Road, Galway, Ireland. siobhan.glavey@nuigalway.ie Received 18 March 2013; revised 11 June 2013; accepted 13 June 2013; published online 5 August 2013
2 1544 was measured in all patients who were not anuric immediately before auto-sct. The cause of kidney disease was recorded as found at renal biopsy report. The stage of MM at the time of auto-sct was defined using Durie Salmon criteria. 3 Post auto-sct SCr was measured between 1 and 3 months to assess the immediate effect of auto-sct on renal function. Long-term renal and hematological outcome data were also collected for all patients until time of analysis or death. Estimated glomerular filtration rate (egfr) was calculated using the modification of diet in renal disease (MDRD) equation. 15 The International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma were used to assess response to auto-sct in all patients. 5 All interval complications were noted, including acute kidney injury, sepsis, mucositis, diarrhea and the need for dialysis in the post transplant follow-up period. Statistical methods The minimally important difference in outcome following auto-sct considered to be clinically significant was avoidance of dialysis for patients with advanced renal impairment and freedom from dialysis for those already requiring it before auto-sct. Descriptive statistics were carried out using SPSS (SPSS Inc., Chicago, IL, USA). For non-parametric analysis of paired samples, we used the Wilcoxon signed-rank test and for unpaired sample data, we used the Mann Whitney U-test. Parametric analysis for paired samples was carried out using the paired samples t-test. Univariate analysis was carried out to determine any association between explanatory variables and renal function following auto-sct. Survival probability curves were constructed using the Kaplan Meier method, and survival was compared using the log-rank test. RESULTS Baseline characteristics Out of 1074 patients, 30 patients (2.8%) had a SCr level over 3 mg/dl or were dialysis dependent before auto-sct for MM. Characteristics of the group are shown in Table 1. The median age was 61 years (range 37 72), 18 patients (60%) were male. The median egfr of the entire group before SCT was 12 ml/min/ 1.73 m 2 and, following auto-sct, the median egfr was higher at 13.1 ml/min/1.73 m 2. Before undergoing auto-sct, eight (26.6%) patients had achieved a PR and a further five patients (16.7%) had achieved a very good partial response, 11 (36.6%) patients had stable disease and four (13.3%) patients had relapsed MM. One patient who was dialysis dependent had achieved a. Nineteen (63.3%) patients were Durie Salmon stage 3(b). Twenty-nine patients (96.6%) received conditioning with melphalan 140 mg/m 2 with one patient receiving melphalan 120 mg/m 2. All patients had either one or two chemotherapy regimens before auto-sct, with one patient having three prior regimens. The cause of renal disease was cast nephropathy seen on renal biopsy in 18/30 patients (60%). Direct plasma cell infiltration was the cause of renal disease in one patient. Acute tubular necrosis was noted on biopsy in seven patients either alone or in association with cast nephropathy. One patient had renal failure attributed to platinum toxicity, and three patients related to non-steroidal use in combination with cast nephropathy. At the time of follow-up, 16 patients were alive. Of the 30 selected patients, 26 (86.7%) had a HR according to International Myeloma Working Group criteria in response to auto-sct, with achieved for 12 patients (40%). One patient in the low-clearance group died in the stemcell mobilization period because of sepsis. There were no early deaths in the group of patients who were dialysis dependent before auto-sct. Dialysis-dependent group Fifteen patients were dialysis dependent at the time of transplantation. All of these patients, except one, were undergoing dialysis three times per week. The median egfr of the eleven patients who had their creatinine clearance measured before auto-sct was 8 ml/min/1.73 m 2 (range 7 14). Six patients had their creatinine clearance measured following auto-sct with a median of Table 1. Patients characteristics Entire cohort Low-clearance group Dialysis-dependent group N Median time from Dx to Auto-SCT (days) Age 61 (37 72) 61 (37 71) 60 (43 72) Sex (male) 18 (60%) 11 (73.3%) 7 (46.6%) Pre auto-sct egfr ml/min/1.73 m 2 12 ( ) 15.0 ( ) 8 (7 14) Post auto-sct egfr ml/min/1.73 m ( ) 19.4 ( ) 11 (8 14) Durie Salmon stage 3(b) 19 (63.3%) 10 (66.6%) 9 (60%) Melphalan dosage 140 mg/m mg/m Number of prior chemotherapy regimens Renal pathology Cast nephropathy Direct plasma cell infiltration 1 1 Acute tubular necrosis Platinum toxicity 1 1 NSAIDS 3 3 Median follow-up (months) 40.7 Pre auto-sct hematological status /VGPR/pPR (n) 1/5/23 0/3/11 1/2/12 Post auto-sct hematological status /VGPR/pPR (n) 12/10/8 5/5/4 7/5/3 Abbreviations: ¼ complete hematological response; Dx ¼ diagnosis; egfr ¼ estimated glomerular filtration rate; NSAIDS ¼ non-steroidal anti-inflammatory drugs; PR¼ partial hematological response; VGPR ¼ very good partial response. Values median and range for GFR and age, others n(%). Bone Marrow Transplantation (2013) & 2013 Macmillan Publishers Limited
3 11 ml/min/1.73 m 2 (range 8 14). One of these patients had an improvement in creatinine clearance from 12 to 18 ml/min of egfr, but attempts to stop dialysis were unsuccessful. The difference in egfr of 3 ml/min/1.73 m 2 was not statistically significant (P ¼ 0.06). The patients who did not have a SCr clearance measured were either anuric or were not clinically expected to have improved renal function based on dialysis parameters. Low-clearance group Fifteen patients were found to have low creatinine clearance; creatinine 43 g/dl, but were not dialysis dependent at the time of transplantation. Baseline characteristics for this group are shown in Table 1 and were comparable to that of the dialysis-dependent group. The median age was 61 years (range 37 71). The median egfr before harvest was 15 ml/min/1.72 m 2 (range ) and post transplant median egfr was19.4 ml/min/1.73 m 2 (range ). The improvement in egfr was statistically significant (P ¼ 0.035) (Figure 1). Only one patient required hemodialysis during the peri-transplant period (day 0 100) This patient s renal function returned to baseline 17 days post auto-sct and dialysis was not required in the long term. Predictors of renal recovery When classifying the entire group of 30 patients based on response status, the median egfr before auto-sct for those who egfr(ml/min/1.73m 2 ) egfr pre auto-sct egfr post auto-sct Low clearance group Figure 1. Boxplot demonstrating median egfr in the low-clearance group pre and post auto-sct. Pre auto-sct ¼ 15.0 ml/min/1.73 m 2. Post auto-sct ¼ 19.4 ml/min/1.73 m 2 (P ¼ 0.035) did not go on to achieve a was 13.2 ml/min/1.73 m 2. Those who did achieve a (n ¼ 12) following auto-sct had a higher median pre-transplant egfr of 17.5 ml/min/1.73 m 2. Following auto-sct, the median egfr for the patients who did not achieve a was 13.5 ml/min/1.73 m 2 and for those who did achieve a, the median egfr was 23.9 ml/min/1.73 m 2, Figure 2b. This improvement in egfr based on response status was not statistically significant for either group (P ¼ 0.52). Importantly, in univariate logistic regression analysis, reponse status was not independently associated with an improvement in egfr regardless of whether patients were dialysis dependent before auto-sct. Furthermore, considering the entire group of 30 patients, on univariate analysis, improvement in egfr was not independently associated with age at auto-sct, renal function before auto-sct or time from MM diagnosis to transplant (Table 2). Long-term follow-up Although initial assessment of renal response was made in the first 3 months following auto-sct, all patients were followed for renal and hematological outcomes over the 10-year study period. During long-term follow-up of the low-clearance group, four patients progressed to end-stage kidney disease following auto- SCT and became dialysis dependent. One of these patients had achieved a following auto-sct, the remaining three patients achieved at least a PR. Of the 15 dialysis-dependent patients, one patient became dialysis independent following auto-sct. This patient s renal function had been improving before auto-sct with an iothalomate clearance of 19 ml/min of egfr. This patient became independent of hemodialysis 17 days after transplantation. This observation was not coincident, at that time, with HR or reduction in plasma or urine paraprotein levels, and iothalamate clearance was unchanged after transplant at 20 ml/min of egfr; however, this patient did go on to achieve a in the long term. In terms of long-term survival, as expected, the OS of patients who were dialysis dependent at the time of auto-sct was shorter than that of patients with low creatinine clearance at 29.3 versus 64.7 months, respectively; log-rank P ¼ 0.06 (Figure 3). Treatment-related toxicity The treatment-related complications in the immediate post transplant period are outlined in Table 3. As previously noted, there was one death in the stem-cell mobilization period. The median time to neutrophil engraftment was 13 days and the median time to platelets/ml platelets was 18 days. egfr pre auto-sct (ml/min/1.73m 2 ) No egfr post auto-sct (ml/min/1.73m 2 ) No Difference in egfr(ml/min/1.73m 2 ) No Figure 2. Median GFR (a) pre and (b) post auto-sct according to response status. The median egfr before auto-sct for those who did not go on to achieve a was 13.2 ml/min/1.73 m 2 vs 17.5 ml/min/1.73 m 2 for those who did. (b) Post auto-sct, the median egfr for the patients who did not achieve a was 13.5 ml/min/1.73 m 2 vs 23.9 ml/min/1.73 m 2 for those who did. (c) The improvement in egfr based on response status was not statistically significant for either group (P ¼ 0.52). & 2013 Macmillan Publishers Limited Bone Marrow Transplantation (2013)
4 1546 Table 2. Predictors of renal recovery following auto-sct Univariate predictor variable b (95% CI) P-value Age egfr pre auto-sct Time to auto-sct Abbreviations: CI ¼ class interval; egfr ¼ estimated glomerular filtration rate. Proportions surviving Low CrCl Dialysis Months since ASCT Figure 3. Kaplan Meier survival probability curve demonstrating the difference in survival for the dialysis-dependent group before auto-sct vs low-clearance group 29.3 vs 64.7 months, respectively. (Log rank P ¼ 0.06). Table 3. Treatment-related toxicity Treatment-related toxicity n (%) Mucositis 11 (36.6%) Line sepsis 7 (23%) Bacteremia 5 (16.6%) Engraftment syndrome 1 (3.3%) Acute kidney injury requiring dialysis 1 (3.3%) DISCUSSION The superiority of high-dose chemotherapy followed by auto-sct in MM has been established with a higher rate of and EFS. 10,12 Renal failure is a common complication of MM at presentation and is seen in B20% of overall cases. 12,16 When deciding on treatment options for these patients, the clinical and prognostic significance of various degrees of impairment of renal function require close attention. For those who have reached ESRD, regaining independence from renal replacement therapy is an extremely important goal. We aimed to address whether auto-sct for MM was associated with an improvement in renal function or freedom from dialysis for patients with severe renal impairment secondary to this disease. We found that auto-sct is safe and efficacious in this challenging group of patients. High rates of HR are achieved and OS is quite respectable, especially in the low CrCl, dialysisindependent group. Unfortunately, there was little evidence of recovery of renal function in either group of patients. In our group of 30 patients with advanced renal impairment, only one patient was able to regain independence from renal replacement therapy after auto-sct. The OS of the dialysis-dependent group was disappointing with a median of o3 years, this might be in part owing to the fact that the majority of these patients were transplanted before the modern era of proteasome inhibitors and immune modulator drugs. Our rate of 40% is similar to that seen in the literature for patients undergoing auto-sct with MM and renal impairment. 1,13 In contrast, it was quite encouraging that among the patients with low creatinine clearance, who were not dialysis dependent, none of them required long-term dialysis post auto- SCT. Only one patient required dialysis in the immediate post transplant period. This possibly reflects the fact that these patients are identified as being at risk, and therefore nephrotoxic insults were minimized and efforts to reverse renal impairment were emphasized. Unfortunately, over time 26.6% of the low CrCl patients progressed to ESRD, which was related in all cases to progression of light chain cast nephropathy in the context of progressive disease. Strengths of this study include the fact that our study population has a high case load of MM with a wide distribution of disease spectrum, making these results generalizable to other transplant populations. Our large cohort over 10 years is suitable to investigate the independent effect of auto-sct on renal function, as the variability in treatment protocols and physician practices is minimal. The study of renal outcomes in MM is difficult because of the heterogeneous nature of MM-associated renal disease. This study contributes greatly to the paucity of data pertaining to the renal outcomes in MM patients post transplantation, particularly those with cast nephropathy and end-stage kidney disease who were well represented in this cohort. Our study has certain limitations. The first is the use of SCr X3 mg/dl as our cutoff, which may have led to the selection of patients with more advanced kidney disease, which is less likely to be reversible and to respond to treatment. However, we were specifically interested in this group of patients who make up the majority of treatment-resistant MM-related renal disease and pose a specific challenge for clinicians. SCr assays are known to be potentially affected by paraproteins that can spuriously elevate the SCr, which means that egfr calculated using SCr could potentially underestimate actual egfr in those with a large paraprotein. Therefore, we measured creatinine clearance or iothalamate clearance when possible, which are more reliable markers of egfr. In conclusion, we identified all patients who had advanced renal impairment or who were dialysis dependent at the time of auto- SCT for MM at our institution over a 10-year period. Previous studies have reported that auto-sct has a favorable impact on renal outcome in MM. According to our data, there is no clinically significant benefit in terms of renal outcome with auto-sct in MM. There is also no evidence from this study that auto-sct retards the progression of severe renal impairment in MM with a 26.6% progression to ESRD in the long term despite high levels of HR. We have found that auto-sct does not lead to deterioration in renal function in these patients and should be considered safe and efficacious in patients with advanced renal impairment. This highlights the importance of early intervention in these patients using effective therapies such as bortezomib in order to reverse renal damage before auto-sct is reached. 17,18 Auto-SCT is not precluded in patients who are dialysis dependent or have advanced renal impairment secondary to MM, however, it is important that these patients are carefully counseled. We propose caution in advising patients before auto- SCT that there is likely to be an improvement in renal function. Outlining realistic goals with patients is important with particular reference to dialysis, which has major quality of life implications for patients. Further studies are needed to help identify risk factors for progression of renal disease in these patients and to optimize patient selection for auto-sct. CONFLICT OF INTEREST The authors declare no conflict of interest. Bone Marrow Transplantation (2013) & 2013 Macmillan Publishers Limited
5 REFERENCES 1 Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: San Miguel JF, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol 2010; 89: Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009; 27: Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 2003; 348: Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysisdependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28: Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: & 2013 Macmillan Publishers Limited Bone Marrow Transplantation (2013)
Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma
Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma Gaurav C. Parikh, 1 Ali Imran Amjad, 2 Rima M. Saliba, 1 Syed M. A. Kazmi, 3 Ziad U. Khan,
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationBortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
Original Article Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment Guangzhong Yang, Wenming Chen, Yin Wu Department
More informationMyeloma Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
(24) 33, 823 828 & 24 Nature Publishing Group All rights reserved 268-3369/4 $25. www.nature.com/bmt Myeloma Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative
More informationMedical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012
Medical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012 Support AL Amyloidosis (Light Chain Amyloidosis) Effective Date: 01/01/2013 Document: ARB0413:01 Revision Date: 10/24/2012 Code(s):
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More information& 2005 Nature Publishing Group All rights reserved /05 $
(2005) 35, 985 990 & 2005 Nature Publishing Group All rights reserved 0268-3369/05 $30.00 www.nature.com/bmt Melphalan 200 mg/m 2 with blood stem cell support as first-line myeloma therapy: impact of glomerular
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/125425
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationThe impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation
Nephrol Dial Transplant (2016) 31: 1284 1289 doi: 10.1093/ndt/gfv328 Advance Access publication 30 November 2015 Original Article The impact of dialysis on the survival of patients with immunoglobulin
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationKEY WORDS: Myeloma, Renal insufficiency, Thalidomide, Autologous transplantation
Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency Patrizia Tosi, Elena Zamagni, Paola
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationRole of Suppressed Immunoglobulins in Outcome of Patients With Multiple Myeloma
Multidisciplinary Cancer Investigation October 2017, Volume 1, Issue 4 DOI: 10.21859/mci-01041 Original Article Role of Suppressed Immunoglobulins in Outcome of Patients With Multiple Myeloma Hasan Jalaeikhoo
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationMYBORPRE. Protocol Code. Lymphoma, Leukemia/BMT. Tumour Group. Dr. Kevin Song. Contact Physician
BC Cancer Protocol Summary for the Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant Protocol Code Tumour Group Contact
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationKEY WORDS: Multiple myeloma, Autologous transplantation, Induction therapy
Short Course Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma Cristina
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationBortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
VOLUME 45 ㆍ NUMBER 3 ㆍ September 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma Se
More informationRetrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma
930 Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma NIAN LIU, HEBING ZHOU, GUANGZHONG YANG, CHUANYING GENG, YUAN JIAN, HUAN GUO and WENMING CHEN Department
More informationRenal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement
Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement SILVIA PARK 1*, BORAM HAN 1,2*, KIHYUN KIM 1, SEOK JIN KIM 1, JUN
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationShould some patients with Smoldering Myeloma receive treatment? Yes-High Risk SMM should S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Should some patients with Smoldering Myeloma receive treatment? Yes-High Risk SMM should S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationASBMT. Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Biol Blood Marrow Transplant 19 (2013) 445e449 Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma Emilie Lemieux 1,y, Cyrille Hulin 2,y, Denis Caillot 3, Stéphanie Tardy
More informationModified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
ORIGINAL ARTICLE 218 Oct 26. [Epub ahead of print] https://doi.org/1.394/kjim.218.144 Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
More informationJunru Liu*, Juan Li*, Beihui Huang, Dong Zheng, Mei Chen, Zhenhai Zhou, Duorong Xu, Waiyi Zou
Original Article Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma Junru Liu*, Juan
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationAperTO - Archivio Istituzionale Open Access dell'università di Torino
AperTO - Archivio Istituzionale Open Access dell'università di Torino Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis
More informationHematopoietic Stem-Cell Transplantation for Primary Amyloidosis. Original Policy Date
MP 7.03.29 Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationBiology of Blood and Marrow Transplantation 12: (2006) 2006 American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 12:837-844 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1208-0006$32.00/0 doi:10.1016/j.bbmt.2006.04.006 New Staging Systems
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationProtocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis
Protocol Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis (80142) Medical Benefit Effective Date: 04/01/13 Next Review Date: 07/15 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10,
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationUrinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy Related Kidney Diseases
Article Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy Related Kidney Diseases Nelson Leung,* Morie Gertz,* Robert A. Kyle,* Fernando C. Fervenza,
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationSecond Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda, 1 Joseph Mikhael, 2 Andrew Winter, 1 Norman
More informationABSTRACT 166 Holmium-DOTMP is a beta-emitting radiophosphonate that localizes specifically to the bone surfaces and
Biology of Blood and Marrow Transplantation 13:543-549 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1305-0001$32.00/0 doi:10.1016/j.bbmt.2006.12.448 Results of a Retrospective
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationCitation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationSheena Surindran Grand Rounds 2/15/11
Sheena Surindran Grand Rounds 2/15/11 Affects 5 12 person per million / year 5 10% associated with myeloma Median survival without treatment is 12 40 months Most commonly affected organs are kidney, heart
More informationBackground Information
What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome
More informationAHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1.
AHFS Final Determination of Medical Acceptance: Off-label Use of Bortezomib in Combination with Doxorubicin and Dexamethasone as Inductionn Therapy for Newly Diagnosed Multiple Myeloma in Transplant-eligible
More informationKEY WORDS: Multiple myeloma, Complete remission, Prognostic factor, Overall survival, Autologous stem cell transplantation
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Jin Seok Kim,
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationRetrospective Analysis of 345 Multiple Myeloma Cases: An Investigation from 2 Institutions
Arch Iran Med. September 2018;21(9):412-417 http www.aimjournal.ir Original Article ARCHIVES OF IRANIAN MEDICINE Open Access Retrospective Analysis of 345 Multiple Myeloma Cases: An Investigation from
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationEvaluation of the Feasibility and Efficacy of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma
ORIGINAL ARTICLE Evaluation of the Feasibility and Efficacy of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Tsuyoshi Muta 1, Toshihiro Miyamoto 1, Tomoaki Fujisaki 2,
More informationSerum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial
Serum Free Light Chains should be the target of response evaluation in light chain myeloma rather than urines: results from the IFM 2009 trial Jill Corre*, Thomas Dejoie, Helene Caillon, Michel Attal*,
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationCyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia Houry Leblebjian, PharmD, Kimberly Noonan, NP, Claudia Paba-Prada, MD, Steven P. Treon, MD, Jorge J.
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationAge 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant Parneet K. Cheema, Sahar Zadeh, Vishal Kukreti, Donna Reece,
More informationHematopoietic Stem-Cell Transplantation for Primary Amyloidosis
Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis Policy Number: Original Effective Date: MM.07.019 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/26/2013 Section: Transplants
More informationBence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy
CASE REPORT Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy Wakaba Yamaguchi 1,NaofumiYui 1, Toshikage Nagao
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationHow we manage autologous stem cell transplantation for patients with multiple myeloma
How I Treat From www.bloodjournal.org by guest on May 4, 2018. For personal use only. How we manage autologous stem cell transplantation for patients with multiple myeloma Morie A. Gertz 1 and David Dingli
More informationTrends in day 100 and 2-year survival after auto-sct for AL amyloidosis: outcomes before and after 2006
(2011) 46, 970 975 & 2011 Macmillan Publishers Limited All rights reserved 0268-3369/11 www.nature.com/bmt ORIGINAL ARTICLE Trends in day 100 and 2-year survival after auto-sct for AL amyloidosis: outcomes
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationSuccessful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy
CASE REPORT Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy Naohiro Sekiguchi 1, Naoki Takezako 1, Akihisa Nagata 1, Miyuki Wagatsuma 2, Satoshi Noto 1, Kazuaki
More informationPrognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
(2004) 34, 235 239 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $30.00 www.nature.com/bmt Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose
More informationEBMT2008_22_44:EBMT :26 Pagina 424 CHAPTER 27. HSCT for primary amyloidosis in adults. J. Esteve
EBMT2008_22_44:EBMT2008 6-11-2008 9:26 Pagina 424 * CHAPTER 27 HSCT for primary amyloidosis in adults J. Esteve EBMT2008_22_44:EBMT2008 6-11-2008 9:26 Pagina 425 CHAPTER 27 Amyloidosis in adults 1. Introduction
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationUltra High-Risk Myeloma
UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGIC MALIGNANCIES Ultra High-Risk Myeloma Hervé Avet-Loiseau 1 1 Laboratoire d Hématologie, Institut de Biologie, Nantes, France Ultra high-risk myeloma
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More information